Sponsored By:

4 Pharmaceutical Stocks to Buy Now

OMER, WPI, QCOR, CORT improve in weekly rankings

   

This week, four pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, Omeros Corporation (OMER) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Omeros is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. For more information, get Portfolio Grader’s complete analysis of OMER stock.

This week, Watson Pharmaceuticals (WPI) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Questcor Pharmaceuticals, Inc. (QCOR) boosts its rating from a B to an A this week. Questcor Pharmaceuticals develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. For more information, get Portfolio Grader’s complete analysis of QCOR stock.

This week, Corcept Therapeutics Incorporated. (CORT) pushes up from a C to a B rating. Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. For more information, get Portfolio Grader’s complete analysis of CORT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2014/01/4-pharmaceutical-stocks-to-buy-now-omer-wpi-qcor/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.